Does New Study Question Need for Pediatric COVID-19 Vaccines?
Pfizer, Moderna, Bharat Conducting Trials
A recent study says a cohort of unvaccinated individuals aged under 16 years in Israel showed a nearly two-fold decrease in COVID-19 positivity for each 20 percentage points of individuals vaccinated overall. As Pfizer, Moderna and Bharat Biotech develop pediatric vaccines, should they consider if herd immunity might make such vaccines redundant?
You may also be interested in...
A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
In this week's podcast edition of Scrip's Five Must-Know Things: new developments in the TIGIT field; doctor frustration over Aduhelm guidance; are pediatric COVID vaccines necessary: the battle of the SERDs; and one Indian firm’s plans for lung disease leadership.